New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

Today's Free Fly Stories
All of the free stories from today.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | all day >>
07:08 EDTDOVDover reports Q1 adjusted EPS $1.01, consensus $1.01
Subscribe for More Information
07:07 EDTSHWSherwin-Williams sees 2014 EPS $8.12-$8.32, consensus $8.45
Subscribe for More Information
07:07 EDTPEPPepsiCo targets $10B in cash flow from operating activities in 2014
Targets more than $7B in free cash flow in 2014. Net capital spending is expected to be approximately $3B in 2014, within the company's long-term capital spending target of less than or equal to 5% of net revenue.
07:06 EDTBHPBHP could benefit from rebound not spinoffs amid metal slump, Bloomberg says
Subscribe for More Information
07:06 EDTPEPPepsiCo sees FY14 organic revenue to grow mid-single digits, consensus $67.17B
Subscribe for More Information
07:06 EDTATRSAntares Pharma says ARD publishes results from OTREXUP study
Antares Pharma announced that the Annals of the Rheumatic Diseases has published results from an open-label, head-to-head randomized, crossover study comparing the relative bioavailability, safety and tolerability of OTREXUP to oral methotrexate in adult patients with rheumatoid arthritis. In this multicenter, three-way crossover study, patients greater than or equal to 18 years old with adult RA undergoing treatment with MTX for three months or more were assigned to receive one of four dose levels of OTREXUP, 10 mg, 15 mg, 20 mg, and 25 mg weekly in a random sequence of three treatments: oral, subcutaneous into the abdomen and subcutaneous into the thigh. For 24 hours after the administration of each treatment, blood samples were collected to measure drug levels and injection sites were assessed. Forty-seven patients completed the study and the results showed that the systemic availability of methotrexate following oral dosing plateaus at 15 mg and greater. Following administration of OTREXUP, the systemic availability increased proportionally at every dose, which extended the range of exposure compared to patients receiving oral therapy. No unexpected adverse events were noted for either formulation in this short term study and higher systemic MTX exposure was not associated with increases in adverse events.
07:06 EDTPEPPepsiCo expects foreign exchange to have negative impact on FY core EPS
Subscribe for More Information
07:05 EDTSHWSherwin-Williams sees Q2 EPS $2.80-$3.00, consensus $2.86
Subscribe for More Information
07:05 EDTMDRMcDermott signs agreement for North Sea spoolbase
McDermott announced that one of its subsidiaries has signed an option agreement with PD Ports which gives it the exclusive right to operate a spoolbase to serve projects in the North Sea. McDermott expects to have the facility available for projects in early FY15. Located in Hartlepool, in northeast U.K., the spoolbase is expected to support McDermott’s re-entry into the North Sea Reel-Lay market.
07:05 EDTPMPhilip Morris says FY14 EPS outlook increased due to forex impact
Subscribe for More Information
07:05 EDTPEPPepsiCo on track to deliver $1B in annual productivity savings in 2014
Subscribe for More Information
07:05 EDTAHHArmada Hoffler to develop shopping center in Williamsburg, VA
Armada Hoffler Properties announced that it will develop a grocery-anchored shopping center in Williamsburg, Virginia as part of a joint venture partnership in which the company is the majority partner. This multi-phased project is a redevelopment of the Williamsburg Outlet Mall with the completion of phase one, consisting of approximately 88,000 square feet, expected in early 2016. The company has signed a 20-year lease for approximately 53,000 square feet with Harris Teeter, which will anchor an additional 35,000 square feet of shops and restaurants. The company expects to begin construction on phase one in the third quarter of 2014. Phase two represents an opportunity to develop another 42,000 square feet in the future.
07:05 EDTPEPPepsiCo backs FY14 core EPS 7% growth, consensus $4.53
Subscribe for More Information
07:05 EDTPAH, CHMTPlatform Specialty Products to acquire CAS from Chemtura for about $1B
Subscribe for More Information
07:05 EDTFX Update
FX Update: The dollar maintained a generally soft tone following Yellen's dovish speech yesterday. Trade was quiet in Europe with some countries already off for the long Easter weekend. EUR-USD rose to a new high for the week of 1.3864. Cable, already underpinned following yesterday's stellar labour market data, edged out a fresh five-year high of 1.6842. USD-JPY dipped under 102.00, to a low of 101.86 before settling around 102.00-102.10. AUD-USD initially rose in early Sydney trade, but good selling interest was seen form 0.9390 and the pair drifted back to the 0.9440 area during the European AM session. Data didn't have bearing today. Eurozone March PPI came in slightly below expectations at -0.9% y/y. The Reuters Tankan report found the headline Japan manufacturers index up 7 points, and the non-manufacturers index rising to a record. Australia's NAB Q1 quarterly business confidence survey dipped to a reading of 6, after 8 in Q4.
07:04 EDTSHWSherwin-Williams reports Q1 EPS $1.14, consensus $1.11
Subscribe for More Information
07:04 EDTSNASnap-On sees FY14 CapEx $70M-$80M
Subscribe for More Information
07:04 EDTBAXBaxter reports Q1 BioScience revenue $1.61B
Reports Q1 Medical Products sales $2.34B.
07:04 EDTPMPhilip Morris now sees FY14 EPS $5.09-$5.19, may not compare to consensus $5.12
Subscribe for More Information
07:03 EDTBAXBaxter sees Q2 EPS before special items $1.18-$1.22, consensus $1.28
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | all day >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use